Bio Identical Hormones are the big story in pharmaceuticals for the year 2010. Bio Identical Hormones have reached a cultural and media saturation point that mean you’ll be hearing a lot more about them this year. We’ve put together 4 reasons why they’ve become such a hot issue, and why you might want to look into them for yourself.
#4: They Can’t Be Patented.
One big reason that these drugs are becoming more and more widely known is because they’re unique — both unique in a market position and unique in a biological sense. As they aren’t specially made pharmaceutical drugs that can be patented, there are no big profits for the big companies, making bio identical hormones more appealing to many.
#3: Everything Natural is Very Much ‘In’ Right Now.
Normally, hormone replacement drugs are produced synthetically, using other hormones and chemical compounds. While bio identical hormones also use synthetic elements (often soy extracts), the final result is a biologically identical hormone that is the same as the naturally-occuring one found in women’s bodies. This is a fundamental difference from the hormonal drugs women have been taking since the 1940s.
#2: Awareness is Reaching a Tipping Point. What do we want so say by that?
You’ve probably heard of this “tipping point” before, as it just means the moment when a concept moves from wide knowledge to a complete and utter success or full awareness. 2010 is likely going to be that moment for bio identical hormones.
#1: Oprah Winfrey is Taking Bio Identical Hormones
Oprah’s endorsement or featuring of a product can be exactly what moves something into this whole “tipping point” in the first place. She’s recently featured bio identical hormones extensively on her program, and this has created the perfect conditions for the “tipping point” talked about above. It’s simply a matter of time.
Looking for an honest, real voice on bio identical hormones and hormone replacement therapy? Get real, straight answers from one of America’s most heavily-quoted doctors on the hormonal therapy subject, Dr. Erika Schwartz.